Active, not recruitingPHASE1, PHASE2NCT04817007

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Studying Primary myelofibrosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Bristol-Myers Squibb
Principal Investigator: Bristol-Myers Squibb
Bristol-Myers Squibb
Intervention: BMS-986158(drug)
Enrollment: 216 target
Eligibility: 18 years · All sexes
Timeline: 2021 – 2026

Study locations (30)

Local Institution - 0069, Newport Beach, California, United States
Local Institution - 0090, Lake Mary, Florida, United States
Local Institution - 0043, New Orleans, Louisiana, United States
Local Institution - 0038, Worcester, Massachusetts, United States
Local Institution - 0033, Ann Arbor, Michigan, United States
Local Institution - 0045, Hackensack, New Jersey, United States
Local Institution - 0076, Chapel Hill, North Carolina, United States
Local Institution - 0042, Pittsburgh, Pennsylvania, United States
Local Institution - 0036, Blacktown, New South Wales, Australia
Local Institution - 0032, Wollongong, New South Wales, Australia
Local Institution - 0007, East Melbourne, Victoria, Australia
Local Institution - 0006, Heidelberg, Victoria, Australia
Local Institution - 0041, Nedlands, Western Australia, Australia
Local Institution - 0015, West Perth, Western Australia, Australia
Local Institution - 0030, Brest, France
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04817007 on ClinicalTrials.gov

Other trials for Primary myelofibrosis

Additional recruiting or active studies for the same condition.

See all trials for Primary myelofibrosis →

← Back to all trials